PepGen shares almost double as DM1 oligonucleotide achieves ‘best in class’ splicing

Mean splicing correction for PepGen’s PGN-EDODM1 was 46.5% at week 13, compared to under 30% for competitors like Dyne Therapeutics, Novartis and Ionis Pharmaceuticals.